U.S. Stock Market Midday Update

Aardvark Therapeutics rose 12.22%. Based on recent key news:

1. On August 21, Aardvark Therapeutics was accused of misleading investors about the commercial prospects of its ARD-101 drug candidate during its IPO. This incident triggered legal actions from investors, leading to stock price volatility.

2. On August 21, Shareholders Foundation issued a notice reminding investors about the relevant information regarding the securities class action lawsuit, further intensifying market attention on Aardvark.

3. On August 20, Hagens Berman Sobol Shapiro LLP highlighted its successful experience in handling corporate negligence cases, attracting more investor attention to Aardvark's legal issues. The legal litigation increases market uncertainty.

Stocks with High Trading Volume in the Industry

Eli Lilly rose 1.79%. Based on recent key news:

1. On August 20, Eli Lilly signed a collaboration agreement with Amplitude Therapeutics to jointly develop a trans-amplifying RNA vaccine candidate for infectious diseases. The financial terms of this collaboration were not disclosed, and the two companies will initially focus on vaccine projects with high unmet medical needs. Eli Lilly will be responsible for subsequent preclinical development, clinical development, manufacturing, regulatory affairs, and commercialization. This collaboration marks Eli Lilly's strategic move in the RNA technology field, driving the stock price up. Source: Guandian.com

2. On August 19, during U.S. trading hours, Eli Lilly's stock price rose 5.3% to $1,290 per share, setting a new record high, with a total market capitalization of $1.21 trillion. The core driver of the company's performance comes from the GLP-1 diabetes and weight loss drug portfolio, with strong market demand for Mounjaro and Zepbound, and the second-quarter revenue and profit significantly exceeding market expectations. The company also raised its full-year performance guidance, and the oral GLP-1 new drug has achieved commercialization. Source: Daily Economic News

3. On August 19, Eli Lilly reported second-quarter revenue of $7.967 billion, a nearly 50% year-on-year increase. Sales were primarily driven by weight loss drugs Zepbound and Mounjaro, continuing to benefit from strong consumer demand. Eli Lilly controls about 60% of the U.S. weight loss drug market. Source: MarketBeat The innovative drug sector is welcoming investment opportunities, with a dense release of clinical data throughout the year.

Merck rose 1.94%, with increased trading volume. Based on recent key news:

1. On August 19, Merck and Moderna jointly announced that their personalized mRNA cancer vaccine achieved success in Phase III clinical trials, reducing the risk of melanoma recurrence. This news propelled Merck's stock price to a historic high, with an increase of up to 8.2%. Source: Guandian.com

2. On August 20, the Hong Kong Economic Journal reported that the vaccine developed by Moderna in collaboration with Merck has sparked heated discussions in the market, leading to a surge in Moderna's stock price, with Merck also benefiting from this, demonstrating the market's high expectations for new therapies. Source: Hong Kong Economic Journal

3. On August 21, TD Cowen maintained a "Hold" rating on Merck. Despite the success of the vaccine, uncertainties remain, with a target price set at $137. Source: TD Cowen analysis report. The pharmaceutical sector is affected by AI trading rotation, with significant capital inflows.

Johnson & Johnson rose by 1.58%, with increased trading volume. Based on recent key news:

1. On August 19, Johnson & Johnson faces challenges from biosimilar competition and sluggish growth in its MedTech division. The growth of its core innovative drug sector is impacted by intensified biosimilar competition, leading to revenue pressure and margin compression.

2. On August 19, insider trading by Johnson & Johnson executives has drawn attention. CEO Joaquin Duato sold over 123,000 shares in mid-August, and the uncertainty surrounding executive changes has heightened market concerns about the company's future.

3. On August 22, lawsuits related to talc products continue to pressure the company. The company has agreed to resolve related cases for at least $5.5 billion, indicating the ongoing presence of legal risks. The biopharmaceutical industry faces intensified competition and growth pressures.

Stocks ranked among the top in industry market capitalization

Novartis rose by 1.75%. Based on recent news:

1. On August 19, Novartis showcased 10 abstracts at the 2026 European Society of Cardiology Congress, highlighting its innovative achievements in the cardiovascular field. These data demonstrate Novartis's progress in cardiovascular science for high-risk patients, boosting market confidence in its products and driving stock price increases.

2. On August 20, an analysis report from CMB International pointed out that multinational pharmaceutical companies will face a patent cliff over the next three years, with risk exposure exceeding 20%. Novartis is adjusting its strategic layout in China, deepening its local market presence, which has enhanced investor confidence in its long-term development, resulting in a stock price increase.

3. On August 21, Boehringer Ingelheim's Shanghai Zhangjiang production base has become an important production and supply center in the Asia-Pacific region, planning to start local production of the innovative drug Boehringer Ingelheim in the third quarter. The upgrade of production and supply chains by multinational pharmaceutical companies in China highlights the importance of the Chinese market, further driving Novartis's stock price increase. Strategic adjustments and innovation upgrades by multinational pharmaceutical companies in the Chinese market